Objective: In a previous cross-sectional pilot investigation, an increase in the ratio of active cortisol to inactive cortisone in serum has been found as a general phenomenon during the acute-phase response. The aim of the present study was to further characterize this alteration of cortisol metabolism in patients undergoing elective cardiac bypass surgery. Methods: Cortisol and cortisone were quantified by use of liquid-chromatography tandem mass spectrometry in sera that were sampled preoperatively and on the first 4 postoperative days (POD) from 16 patients undergoing aortocoronary bypass grafting (7.00 a.m.). Results: The median serum cortisol concentration peaked on the first POD and then decreased statistically significantly until the end of the observation period: preoperatively, 245 nmol/l (IQR 198–331); 1st POD, 532 nmol/l (IQR 409–678 ); 4th POD, 373 nmol/l (IQR 306–493); p for trend = 0.019. In contrast, the cortisol:cortisone ratio was constantly increased approximately twofold on all POD compared to preoperative sampling: preoperatively, 5.4 (IQR 5.0–7.2); 1st POD, 11.3 (IQR 9.2–13.6); 4th POD, 9.9 (IQR 7.7–11.0), with no significant trend of normalization. Conclusion: Following major surgery, the substantial increase in the serum cortisol:cortisone ratio – reflecting a shift in the overall set-point of 11β-hydroxysteroid dehydrogenase activity – is more sustained than the increase in serum cortisol; the increase in the cortisol:cortisone ratio seems to be a long-term phenomenon of the activation of the hypothalamic-pituitary-adrenocortical system by surgical stress and systemic inflammation.

1.
Oppermann UC, Persson B, Jornvall H: Function, gene organization and protein structures of 11beta-hydroxysteroid dehydrogenase isoforms. Eur J Biochem 1997;249:355–360.
2.
Krozowski Z, Li KX, Koyama K, Smith RE, Obeyesekere VR, Stein-Oakley A, Sasano H, Coulter C, Cole T, Sheppard KE: The type I and type II 11beta-hydroxysteroid dehydrogenase enzymes. J Steroid Biochem Mol Biol 1999;69:391–401.
3.
Ricketts ML, Verhaeg JM, Bujalska I, Howie AJ, Rainey WE, Stewart PM: Immunohistochemical localization of type 1 11beta-hydroxysteroid dehydrogenase in human tissues. J Clin Endocrinol Metab 1998;83:1325–1335.
4.
Vogeser M, Zachoval R, Jacob K: Serum cortisol/cortisone ratio after Synacthen stimulation. Clin Biochem 2001;34:421–425.
5.
Vogeser M, Zachoval R, Felbinger TW, Jacob K: Increased ratio of serum cortisol to cortisone in acute-phase response. Horm Res 2002;58:172–175.
6.
Vogeser M, Briegel J, Jacob K: Determination of serum cortisol by isotope-dilution liquid-chromatography electrospray ionization tandem mass spectrometry with on-line extraction. Clin Chem Lab Med 2001;39:944–947.
7.
Whitworth JA, Stewart PM, Burt D, Atherden SM, Edwards CR: The kidney is the major site of cortisone production in man. Clin Endocrinol 1989;31:355–361.
8.
Dötsch J, Dorr HG, Stalla GK, Sippell WG: Effect of glucocorticoid excess on the cortisol/cortisone ratio. Steroids 2001;66:817–820.
9.
Quinkler M, Troeger H, Eigendorff E, Maser-Gluth C, Stiglic A, Oelkers W, Bahr V, Diederich S: Enhanced 11beta-hydroxysteroid dehydrogenase type 1 activity in stress adaptation in the guinea pig. J Endocrinol 2003;176:185–192.
10.
Voice MW, Seckl JR, Edwards CRW, Chapman KE: 11β-Hydroxysteroid dehydrogenase type I expression in 2S FAZA hepatoma cells is hormonally regulated: A model system for the study of hepatic glucocorticoid metabolism. Biochem J 1996;317:621–625.
11.
Napolitano A, Voice MW, Edwards CR, Seckl JR, Chapman KE: 11β-Hydroxysteroid dehydrogenase 1 in adipocytes: Expression is differentiation-dependent and hormonally regulated. J Steroid Biochem Mol Biol 1998;64:251–260.
12.
Ricketts ML, Shoesmith KJ, Hewison M, Strain A, Eggo MC, Stewart PM: Regulation of 11β-hydroxysteroid dehydrogenase type 1 in primary cultures of rat and human hepatocytes. J Endocrinol 1998;156:159–168.
13.
Jamieson PM, Nyirenda MY, Walker BR, Chapman KE, Seckl JR: Interactions between oestradiol and glucocorticoid regulatory effects on liver-specific glucocorticoid-inducible genes: Possible evidence for a role in hepatic 11β-hydroxysteroid dehydrogenase type 1. J Endocrinol 1999;160:103–109.
14.
Escher G, Galli I, Vishwanath BS, Frey BM, Frey FJ: Tumor necrosis factor alpha and interleukin-1beta enhance the cortisone/cortisol shuttle. J Exp Med 1997;186:189–198.
15.
Cai TQ, Wong B, Mundt SS, Thieringer R, Wright SD, Hermanowski-Vosatka A: Induction of 11beta-hydroxysteroid dehydrogenase type 1 but not 2 in human aortic smooth muscle cells by inflammatory stimuli. J Steroid Biochem Mol Biol 2001;77:117–122.
16.
Cooper MS, Bujalska I, Rabbitt E, Walker EA, Bland R, Sheppard MC, Hewison M, Stewart PM: Modulation of 11beta-hydroxysteroid dehydrogenase isozymes by proinflammatory cytokines in osteoblasts: An autocrine switch from glucocorticoid inactivation to activation. J Bone Miner Res 2001;16:1037–1044.
17.
Schleimer RP: Potential regulation of inflammation in the lung by local metabolism of hydrocortisone. Am J Respir Cell Mol Biol 1991;4:166–173.
18.
Edwards CR, Benediktsson R, Lindsay RS, Seckl JR: 11beta-Hydroxysteroid dehydrogenases: Key enzymes in determining tissue-specific glucocorticoid effects. Steroids 1996;61:263–269.
19.
Rook G, Baker R, Walker B, Honour J, Jessop D, Hernandez-Pando R, Arriaga K, Shaw R, Zumla A, Lightman S: Local regulation of glucocorticoid activity in sites of inflammation: Insights from the study of tuberculosis. Ann NY Acad Sci 2000;917:913–922.
20.
Vogeser M, Gülberg V, Waggershauser T, Gerbes AL: In-vivo quantification of hepatic 11β-hydroxysteroid dehydrogenase type I activity – A preliminary study. Clin Biochem 2002;35:655–657.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.